SECsense Logo

Tiziana Life Sciences' Form 6-K: Breakthrough in Alzheimer's Treatment Announced

$TLSA
Form 6-K
Filed on: 2024-12-17
Source
Tiziana Life Sciences' Form 6-K: Breakthrough in Alzheimer's Treatment Announced

Here are the key insights extracted from the financial report (Form 6-K) of Tiziana Life Sciences LTD:

  1. Company Overview:
  • Name: Tiziana Life Sciences LTD
  • Commission File Number: 001-38723
  • Principal Executive Office Address:
    • 107 Cheapside, London, EC2V 6DN, UK
  1. Filing Type:
  • This document is a Form 6-K, which is used by foreign private issuers to report significant events.
  1. Reporting Date:
  • The report was issued on December 17, 2024.
  1. Significant Milestone:
  • Tiziana Life Sciences announced a major advancement in its clinical development program for Alzheimer's disease.
  • The company successfully dosed the first patient with moderate Alzheimer's disease using intranasal foralumab at Brigham and Women’s Hospital in Boston, Massachusetts. This follows a baseline PET scan for the patient.
  1. Exhibit Information:
  • The details regarding this milestone are further elaborated in Exhibit 99.1, which is included with the report.
  • The information in Exhibit 99.1 is being furnished and is not considered "filed" under the Securities Exchange Act of 1934, which affects its legal standing.
  1. Signature:
  • The report is signed by Keeren Shah, Chief Financial Officer of Tiziana Life Sciences LTD, indicating that the information is duly authorized.
  1. Clinical Development Context:
  • The dosing of the first patient is a significant step in the clinical trials for Alzheimer's treatment, suggesting progress in the company's research and potential future therapeutic applications.

This report reflects important developments in Tiziana Life Sciences' operations and underlines their focus on Alzheimer’s disease treatment, which may impact their stock performance and investor interest.